Michelle Arkin

Summary

Affiliation: Sunesis Pharmaceuticals
Country: USA

Publications

  1. ncbi Binding of small molecules to an adaptive protein-protein interface
    Michelle R Arkin
    Department of Biology, Sunesis Pharmaceuticals, South San Francisco, CA 94080 1913, USA
    Proc Natl Acad Sci U S A 100:1603-8. 2003
  2. ncbi Small-molecule inhibitors of protein-protein interactions: progressing towards the dream
    Michelle R Arkin
    Sunesis Pharmaceuticals, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    Nat Rev Drug Discov 3:301-17. 2004
  3. ncbi Protein-protein interactions and cancer: small molecules going in for the kill
    Michelle Arkin
    Sunesis Pharmaceuticals, 341 Oyster Point Blvd, South San Francisco, California 94080, USA
    Curr Opin Chem Biol 9:317-24. 2005
  4. ncbi Discovery of a potent small molecule IL-2 inhibitor through fragment assembly
    Andrew C Braisted
    Sunesis Pharmaceuticals, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    J Am Chem Soc 125:3714-5. 2003
  5. ncbi Discovery and characterization of cooperative ligand binding in the adaptive region of interleukin-2
    Jennifer Hyde
    Sunesis Pharmaceuticals, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    Biochemistry 42:6475-83. 2003
  6. ncbi Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions
    Brian C Raimundo
    Sunesis Pharmaceuticals Inc, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    J Med Chem 47:3111-30. 2004
  7. ncbi Identification of nonpeptidic small-molecule inhibitors of interleukin-2
    Nathan D Waal
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 15:983-7. 2005

Collaborators

Detail Information

Publications7

  1. ncbi Binding of small molecules to an adaptive protein-protein interface
    Michelle R Arkin
    Department of Biology, Sunesis Pharmaceuticals, South San Francisco, CA 94080 1913, USA
    Proc Natl Acad Sci U S A 100:1603-8. 2003
    ..Thus, the adaptive nature of a protein-protein interface provides sites for small molecules to bind and underscores the challenge of applying structure-based design strategies that cannot accurately predict a dynamic protein surface...
  2. ncbi Small-molecule inhibitors of protein-protein interactions: progressing towards the dream
    Michelle R Arkin
    Sunesis Pharmaceuticals, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    Nat Rev Drug Discov 3:301-17. 2004
  3. ncbi Protein-protein interactions and cancer: small molecules going in for the kill
    Michelle Arkin
    Sunesis Pharmaceuticals, 341 Oyster Point Blvd, South San Francisco, California 94080, USA
    Curr Opin Chem Biol 9:317-24. 2005
    ..Not only is the list of protein-protein inhibitors growing, but the inhibitors themselves are moving closer to treating disease...
  4. ncbi Discovery of a potent small molecule IL-2 inhibitor through fragment assembly
    Andrew C Braisted
    Sunesis Pharmaceuticals, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    J Am Chem Soc 125:3714-5. 2003
    ..This method of coupling selected fragments with a low micromolar hit shows great potential for generating high-affinity lead compounds...
  5. ncbi Discovery and characterization of cooperative ligand binding in the adaptive region of interleukin-2
    Jennifer Hyde
    Sunesis Pharmaceuticals, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    Biochemistry 42:6475-83. 2003
    ..The tethering approach provides a novel and general strategy for discovering such cooperative binding interactions in specific, flexible regions of protein structure...
  6. ncbi Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions
    Brian C Raimundo
    Sunesis Pharmaceuticals Inc, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    J Med Chem 47:3111-30. 2004
    ..Throughout the discovery process, biophysical methods and structural biology demonstrated that compounds bound reversibly to IL-2 at the IL-2 receptor binding site...
  7. ncbi Identification of nonpeptidic small-molecule inhibitors of interleukin-2
    Nathan D Waal
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 15:983-7. 2005
    ..Installation of a furan carboxylic acid fragment onto a low-micromolar sulfamide resulted in a 23-fold improvement in activity, providing a sub-micromolar, nonpeptidic IL-2 inhibitor (IC(50)=0.60 microM)...